These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37976112)

  • 21. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
    Mysler E; Tanaka Y; Kavanaugh A; Aletaha D; Taylor PC; Song IH; Shaw T; Song Y; DeMasi R; Ali M; Fleischmann R
    Rheumatology (Oxford); 2023 May; 62(5):1804-1813. PubMed ID: 36018230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).
    Kameda H; Takeuchi T; Yamaoka K; Oribe M; Kawano M; Yokoyama M; Pangan AL; Konishi Y; Meerwein S; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):9. PubMed ID: 33407801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
    Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
    J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
    Conaghan PG; Mysler E; Tanaka Y; Da Silva-Tillmann B; Shaw T; Liu J; Ferguson R; Enejosa JV; Cohen S; Nash P; Rigby W; Burmester G
    Drug Saf; 2021 May; 44(5):515-530. PubMed ID: 33527177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
    Sung YK; Lee YH
    Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
    Peterfy CG; Strand V; Friedman A; Hall S; Mysler E; Durez P; Baraliakos X; Enejosa JV; Shaw T; Li Y; Chen S; Song IH
    Rheumatology (Oxford); 2022 Aug; 61(8):3246-3256. PubMed ID: 34897366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
    Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
    Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upadacitinib tartrate in rheumatoid arthritis.
    Stamatis P; Bogdanos DP; Sakkas LI
    Drugs Today (Barc); 2020 Nov; 56(11):723-732. PubMed ID: 33332480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.
    La Barbera L; Rizzo C; Camarda F; Atzeni F; Miceli G; Molica Colella AB; Franchina V; Giardina A; Corrao S; Provenzano G; Bursi R; Foti R; Dal Bosco Y; Debilio C; Luppino F; Colaci M; Aprile ML; Bentivegna M; Cassarà E; Lo Gullo A; De Andres MI; Guggino G
    Clin Exp Rheumatol; 2024 May; 42(5):991-998. PubMed ID: 38197190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating upadacitinib for the treatment of rheumatoid arthritis.
    Mysler E; Lizarraga A
    Expert Opin Pharmacother; 2020 Sep; 21(13):1527-1536. PubMed ID: 32515665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
    Wiland P; Jeka S; Dokoupilová E; Brandt-Jürgens J; Miranda Limón JM; Cantalejo Moreira M; Cabello RV; Jauch-Lembach J; Thakur A; Haliduola H; Brueckmann I; Gaylis NB
    BioDrugs; 2020 Dec; 34(6):809-823. PubMed ID: 33119861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.